Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1/22/26 19:34 | 1/20/26 | RXRX | Health | BioPrd | Biological Products, (No Diag | Gibson Christopher | UT | D | 19 | S.dm | -9,489 | 5.46 | 0 | -1,737 | 1,273 | D | ||||||||||||||||
1/8/26 17:01 | 1/6/26 | RXRX | Health | BioPrd | Biological Products, (No Diag | Borgeson Blake | UT | D | 7 | S | -2,311 | 4.65 | 0 | -497 | 7,110 | D | ||||||||||||||||
12/30/25 19:35 | 12/29/25 | RXRX | Health | BioPrd | Biological Products, (No Diag | Taylor Ben R | UT | O | CFO | 1 | S | -89 | 4.18 | 0 | -21 | 762 | D | |||||||||||||||
12/29/25 17:24 | 12/22/25 | RXRX | Health | BioPrd | Biological Products, (No Diag | Khan Najat | UT | DO | Chief R, | 2 | S.d | -751 | 4.66 | 0 | -161 | 668 | D | |||||||||||||||
11/14/24 19:19 | 11/12/24 | RXRX | Health | BioPrd | Biological Products, (No Diag | Secora Michael | UT | O | CFO | 3 | S.dm | -607 | 6.74 | 0 | -90 | 1,500 | D | |||||||||||||||
10/28/24 17:25 | 10/24/24 | RXRX | Health | BioPrd | Biological Products, (No Diag | Marriott Tina | UT | O | P,COO | 2 | S.d | -80 | 6.66 | 0 | -12 | 521 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |